	US 11,931,348 B2
	Methods of treating elevated plasma cholesterol
Steve Poirier, Montréal (CA); Brent Richard Stranix, Pointe-Claire (CA); and Gaétan Mayer, Montréal (CA)
Assigned to Montréal Heart Institute, Montreal (CA)
Filed by Montréal Heart Institute, Montréal (CA)
Filed on May 23, 2022, as Appl. No. 17/750,698.
Application 17/750,698 is a continuation of application No. 16/759,815, granted, now 11,400,082, previously published as PCT/CA2018/051377, filed on Oct. 30, 2018.
Claims priority of provisional application 62/578,872, filed on Oct. 30, 2017.
Prior Publication US 2023/0088095 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/44 (2006.01); A61K 31/40 (2006.01); A61K 31/436 (2006.01); A61P 3/06 (2006.01)

CPC A61K 31/44 (2013.01) [A61K 31/40 (2013.01); A61K 31/436 (2013.01); A61P 3/06 (2018.01)]

17 Claims

1. A method of lowering low-density lipoprotein (LDL)-cholesterol level in the bloodstream of a subject, the method comprising administering to the subject a LDL-lowering amount of 5-(3-chloro-4-fluoro-phenoxymethyl)-3-hydroxy-4-hydroxymethyl-pyridine-2-carboxylic acid hydroxyamide

a pharmaceutically acceptable salt thereof.